• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Dis (Lond) . SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN

tetano

Editor, Senior Moderator
Infect Dis (Lond)


. 2022 Jan 13;1-7.
doi: 10.1080/23744235.2021.2025421. Online ahead of print.
SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19)


Irina Kislaya[SUP] 1 [/SUP], Paulo Gonçalves[SUP] 2 [/SUP], Verónica Gómez[SUP] 1 [/SUP], Vânia Gaio[SUP] 1 [/SUP], Rita Roquette[SUP] 1 [/SUP], Marta Barreto[SUP] 1 [/SUP], Mafalda Sousa-Uva[SUP] 1 [/SUP], Ana Rita Torres[SUP] 1 [/SUP], Joana Santos[SUP] 1 [/SUP], Rita Matos[SUP] 2 [/SUP], Carla Manita[SUP] 2 [/SUP], João Almeida Santos[SUP] 2 [/SUP], Sofia Soeiro[SUP] 2 [/SUP], Rita de Sousa[SUP] 2 [/SUP], Inês Costa[SUP] 2 [/SUP], Nuno Verdasca[SUP] 2 [/SUP], Raquel Guiomar[SUP] 2 [/SUP], Ana Paula Rodrigues[SUP] 1 [/SUP], ISN2COVID-19 Group



Affiliations

Abstract

Background: Integrated approaches to surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection are important for public health actions. The 2nd National Serological Survey (ISN2COVID-19) aimed to characterize the extent of SARS-CoV-2 infection and vaccine-induced response in the Portuguese population following the third epidemic wave and the launch of the vaccination campaign.
Methods: A cross-sectional study was performed using data on 8463 Portuguese 1-79 years of age, collected in February and March, 2021. SARS-CoV-2 IgM and IgG (anti-nucleoprotein and anti-spike) antibodies were determined in serum samples using Abbott Architect chemiluminescent microparticle assays. Post-infection and vaccine-induced seroprevalence with 95% confidence intervals (95%CI) were estimated in the overall sample and stratified by population characteristics.
Results: The estimated seroprevalence was 15.5% (95%CI:14.6-16.5%), of which 13.5% (95%CI: 12.6-14.4%) was attributable to natural infection and 2.0% (95%CI:1.7-2.4%) to vaccination. The lowest seroprevelence was observed in persons aged 70-79 years (8.9% 95%CI:6.8-11.6), while seroprevalence in children (14.3%; 95%CI:11.5-17.6%) and adolescents (12.9%; 95%CI:10.5-15.7%) was similar to that of persons aged between 20 and 69 years. Of seropositive individuals, 22.6% (95%CI:19.7-25.9%) did not report any symptoms in 6 months prior to interview. Of persons with completed vaccination (2-doses), 98.6% (95%CI: 93.0-99.7%) had specific IgG (anti-S) antibodies.
Conclusions: After the third epidemic wave, the post-infection SARS-CoV-2 seroprevalence was 1.7 times higher than the cumulative incidence based on PCR-testing, but was higher (2.7 times) in children may be due to the high proportion of asymptomatic and mild infections.

Keywords: COVID-19; Portugal; Seroprevalence; seroepidemiological survey; severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom